Literature DB >> 16505274

Claudins in differential diagnosis between mesothelioma and metastatic adenocarcinoma of the pleura.

Y Soini1, V Kinnula, K Kahlos, P Pääkkö.   

Abstract

AIM: To study the expression of claudins in mesothelioma and metastatic pleural adenocarcinoma.
METHODS: Immunohistochemical staining of claudins 1, 2, 3, 4, 5, and 7 was studied in 35 malignant mesotheliomas and the expression compared with 24 cases of pleural metastatic adenocarcinoma. All cases were also immunostained with calretinin.
RESULTS: Claudin 1, 2, 3, 4, 5, and 7 expression was seen in 40%, 80%, 18%, 23%, 14%, and 43% of mesotheliomas, respectively, while the corresponding figures for adenocarcinoma were 100%, 88%, 90%, 100%, 50%, and 92%. Claudins 1, 3, 4, 5, and 7 were significantly less positive in mesothelioma than in metastatic adenocarcinoma, while no difference was observed for claudin 2. Claudins 1, 3, 4, 5, and 7 were also inversely associated with calretinin positivity. Sarcomatoid and biphasic mesothelioma subtypes appeared more negative for these claudins than pure epithelioid subtypes. Claudin expression was not associated with survival of patients with malignant mesotheliomas.
CONCLUSIONS: The results show that malignant mesotheliomas have a lower expression of claudins 1, 3, 4, 5, and 7 than adenocarcinomas, and their expression could thus be used as an adjunct in differential diagnosis between the two. The difference was most evident for claudins 3 and 4, which were nearly as good as calretinin in mesothelioma detection. Sarcomatoid and biphasic mesotheliomas showed expression of these claudins only occasionally, which could be due to or contribute to their less epithelial appearance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16505274      PMCID: PMC1860350          DOI: 10.1136/jcp.2005.028589

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  21 in total

1.  Heterogeneity in expression and subcellular localization of claudins 2, 3, 4, and 5 in the rat liver, pancreas, and gut.

Authors:  C Rahner; L L Mitic; J M Anderson
Journal:  Gastroenterology       Date:  2001-02       Impact factor: 22.682

2.  Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast.

Authors:  Scott L Kominsky; Pedram Argani; Dorian Korz; Ella Evron; Venu Raman; Elizabeth Garrett; Alan Rein; Guido Sauter; Olli-P Kallioniemi; Saraswati Sukumar
Journal:  Oncogene       Date:  2003-04-03       Impact factor: 9.867

3.  Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer.

Authors:  C D Hough; C A Sherman-Baust; E S Pizer; F J Montz; D D Im; N B Rosenshein; K R Cho; G J Riggins; P J Morin
Journal:  Cancer Res       Date:  2000-11-15       Impact factor: 12.701

4.  Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas.

Authors:  Benoit Terris; Ekaterina Blaveri; Tatjana Crnogorac-Jurcevic; Melanie Jones; Edoardo Missiaglia; Philippe Ruszniewski; Alain Sauvanet; Nicholas R Lemoine
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

5.  Expression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium.

Authors:  H Long; C D Crean; W H Lee; O W Cummings; T G Gabig
Journal:  Cancer Res       Date:  2001-11-01       Impact factor: 12.701

6.  Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin.

Authors:  P Michl; M Buchholz; M Rolke; S Kunsch; M Löhr; B McClane; S Tsukita; G Leder; G Adler; T M Gress
Journal:  Gastroenterology       Date:  2001-09       Impact factor: 22.682

7.  Expression of claudin-1, a recently described tight junction-associated protein, distinguishes soft tissue perineurioma from potential mimics.

Authors:  Andrew L Folpe; Steven D Billings; Jesse K McKenney; Shawn V Walsh; Asma Nusrat; Sharon W Weiss
Journal:  Am J Surg Pathol       Date:  2002-12       Impact factor: 6.394

8.  E-cadherin, E-selectin and vascular cell adhesion molecule: immunohistochemical markers for differentiation between mesothelioma and metastatic pulmonary adenocarcinoma?

Authors:  Annette M Müller; Andreas Weichert; Klaus-Michael Müller
Journal:  Virchows Arch       Date:  2001-11-16       Impact factor: 4.064

9.  The renal segmental distribution of claudins changes with development.

Authors:  Jose Luis Reyes; Monica Lamas; Dolores Martin; Maria del Carmen Namorado; Socorro Islas; Jose Luna; Michel Tauc; Lorenza González-Mariscal
Journal:  Kidney Int       Date:  2002-08       Impact factor: 10.612

10.  Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies.

Authors:  A S Abutaily; B J Addis; W R Roche
Journal:  J Clin Pathol       Date:  2002-09       Impact factor: 3.411

View more
  15 in total

1.  Claudins 10 and 18 are predominantly expressed in lung adenocarcinomas and in tumors of nonsmokers.

Authors:  Heta Merikallio; Paavo Pääkkö; Terttu Harju; Ylermi Soini
Journal:  Int J Clin Exp Pathol       Date:  2011-09-27

Review 2.  Tight junctions in lung cancer and lung metastasis: a review.

Authors:  Ylermi Soini
Journal:  Int J Clin Exp Pathol       Date:  2012-02-12

3.  Claudin-4 expression distinguishes SWI/SNF complex-deficient undifferentiated carcinomas from sarcomas.

Authors:  Inga-Marie Schaefer; Abbas Agaimy; Christopher Dm Fletcher; Jason L Hornick
Journal:  Mod Pathol       Date:  2017-01-13       Impact factor: 7.842

4.  Claudin-1, -2, -3, -4, -7, -8, and -10 protein expression in biliary tract cancers.

Authors:  Zsuzsanna Németh; Attila Marcell Szász; Péter Tátrai; Júlia Németh; Hajnalka Gyorffy; Aron Somorácz; Attila Szíjártó; Péter Kupcsulik; András Kiss; Zsuzsa Schaff
Journal:  J Histochem Cytochem       Date:  2008-10-14       Impact factor: 2.479

Review 5.  Claudins in cancer: bench to bedside.

Authors:  Makoto Osanai; Akira Takasawa; Masaki Murata; Norimasa Sawada
Journal:  Pflugers Arch       Date:  2016-09-13       Impact factor: 3.657

6.  Divergent expression of claudin -1, -3, -4, -5 and -7 in developing human lung.

Authors:  Riitta Kaarteenaho; Heta Merikallio; Siri Lehtonen; Terttu Harju; Ylermi Soini
Journal:  Respir Res       Date:  2010-05-17

7.  Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions.

Authors:  Fabio Facchetti; Silvia Lonardi; Francesca Gentili; Luisa Bercich; Marcella Falchetti; Regina Tardanico; Carla Baronchelli; Laura Lucini; Alessandro Santin; Bruno Murer
Journal:  Virchows Arch       Date:  2007-07-03       Impact factor: 4.064

Review 8.  Claudins as biomarkers of differential diagnosis and prognosis of tumors.

Authors:  Olga P Popova; Alla V Kuznetsova; Svetlana Yu Bogomazova; Alexey A Ivanov
Journal:  J Cancer Res Clin Oncol       Date:  2021-07-09       Impact factor: 4.553

9.  Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma.

Authors:  Oluf Dimitri Røe; Adam Szulkin; Endre Anderssen; Arnar Flatberg; Helmut Sandeck; Tore Amundsen; Sten Even Erlandsen; Katalin Dobra; Stein Harald Sundstrøm
Journal:  PLoS One       Date:  2012-08-08       Impact factor: 3.240

10.  Snail promotes an invasive phenotype in lung carcinoma.

Authors:  Heta Merikallio; Taina Turpeenniemi-Hujanen; Paavo Pääkkö; Riitta Mäkitaro; Kaarteenaho Riitta; Sirpa Salo; Tuula Salo; Terttu Harju; Ylermi Soini
Journal:  Respir Res       Date:  2012-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.